23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
16:11 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension In vitro and mouse studies identified a pyrazolopyrimidinone-based DAPK3/pan-PIM inhibitor that could help treat hypertension. Chemical synthesis and in vitro activity testing of analogs of a pyrazolopyrimidinone-based compound identified a molecule that inhibited...
19:44 , Mar 31, 2017 |  BC Week In Review  |  Company News

Selvita, Menarini deal

Selvita granted Menarini exclusive, worldwide rights to develop and commercialize acute myelogenous leukemia (AML) candidate SEL24 . Selvita will receive an upfront payment of €4.8 million ($5.2 million) and is eligible for up to €89...
20:48 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

SEL24: Ph I/II started

Selvita began an open-label, U.S. Phase I/II trial to evaluate oral SEL24 given once daily for the first 14 days of a 21-day cycle in about 86 patients. The dose-escalation Phase I portion will determine...
23:02 , Nov 17, 2016 |  BC Innovations  |  Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Pim-1 (PIM1); Pim-2 (PIM2)

Cancer INDICATION: Multiple myeloma (MM) In vitro and mouse studies identified a quinazolinone-based inhibitor of PIM1 and PIM2 that could help treat MM. Chemical synthesis and in vitro testing of quinazolinone-pyrrolopyrrolone analogs yielded one compound...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Psoriasis IL-22; pim-1 (PIM1) Mouse studies suggest inhibiting IL-22 or PIM1 could help treat psoriasis. In a xenotransplant mouse model of severe human psoriasis,...
07:00 , Jul 29, 2013 |  BioCentury  |  Emerging Company Profile

Inflection: Pairing up PIM

Inflection Biosciences Ltd. is developing pan-PIM kinase inhibitors that are a few years behind large pharma competitors, but the biotech's compounds can be structurally linked to other kinase inhibitors for cancer. The small molecules thus...
08:00 , Dec 8, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Pim-1 (PIM1); B cell lymphoma 2 (BCL-2; BCL2) Cell culture and mouse studies suggest combining PIM1 and BCL2 inhibitors could help treat prostate...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Company News

Jasco Pharmaceuticals, North Carolina Central University deal

The biotech and university will collaborate to develop therapeutics for pancreatic cancer using Jasco's preclinical selective Pim-1 (PIM1) , PIM2 and PIM3 kinase inhibitors. Further terms were not disclosed. Jasco Pharmaceuticals LLC , Woburn, Mass....